170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 110
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Cezar Andrei Floroiu M.B.A. | CEO, Pres, Principal Financial Officer & Director | 538.15k | N/A | 1973 |
Ms. Margaret A. Echerd | Sr. VP & Principal Accounting Officer | 523.07k | N/A | 1959 |
Dr. Sean N. Tucker | Sr. VP & Chief Scientific Officer | 530.72k | N/A | 1968 |
Mr. Edward B. Berg | Sr. VP & Gen. Counsel | N/A | N/A | N/A |
Ms. Shaily Jaini Garg | Sr. VP of Clinical Devel. & Project Management | N/A | N/A | N/A |
Mr. Brant Biehn | Sr. VP of Bus. Operations | N/A | N/A | N/A |
Dr. Richard M. Schwartz | Sr. VP of Technical Operations | N/A | N/A | N/A |
Dr. Rajesh Kapoor Ph.D. | Sr. VP of Quality | N/A | N/A | N/A |
Dr. James F. Cummings M.D. | Chief Medical Officer | N/A | N/A | N/A |
Mr. John M. Harland M.B.A., CPA | Consultant | N/A | N/A | 1952 |
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Vaxart, Inc.’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 7; Compensation: 8.